Drug/Small Molecule:

flutamide

An antiandrogen with about the same potency as cyproterone in rodent and canine species. (source: Drug Bank)

For the management of locally confined Stage B2-C and Stage D2 metastatic carcinoma of the prostate (source: Drug Bank)

Flutamide is a nonsteroidal antiandrogen that blocks the action of both endogenous and exogenous testosterone by binding to the androgen receptor. In addition Flutamide is a potent inhibitor of testosterone-stimulated prostatic DNA synthesis. Moreover, it is capable of inhibiting prostatic nuclear uptake of androgen. (source: Drug Bank)

Flutamide is a nonsteroidal antiandrogen. In animal studies, flutamide demonstrates potent antiandrogenic effects. It exerts its antiandrogenic action by inhibiting androgen uptake and/or by inhibiting nuclear binding of androgen in target tissues or both. Prostatic carcinoma is known to be androgen-sensitive and responds to treatment that counteracts the effect of androgen and/or removes the source of androgen, e.g. castration. Elevations of plasma testosterone and estradiol levels have been noted following flutamide administration. (source: Drug Bank)

Take without regard to meals. (source: Drug Bank)

Flutamide is rapidly and extensively metabolized, with flutamide comprising only 2.5% of plasma radioactivity 1 hour after administration. (source: Drug Bank)

94-96% (source: Drug Bank)

Rapidly and completely absorbed. (source: Drug Bank)

In animal studies with flutamide alone, signs of overdose included hypoactivity, piloerection, slow respiration, ataxia, and/or lacrimation, anorexia, tranquilization, emesis, and methemoglobinemia. (source: Drug Bank)

CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)N(=O)=O (source: Drug Bank)